Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-11
2011-01-11
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S451000, C514S453000, C514S454000, C514S283000, C540S478000
Reexamination Certificate
active
07868039
ABSTRACT:
The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vinca alkaloids, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vincristine. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.
REFERENCES:
patent: 3678077 (1972-07-01), Nakanishi et al.
patent: 4602034 (1986-07-01), Briet et al.
patent: 4704355 (1987-11-01), Bernstein et al.
patent: 5126129 (1992-06-01), Wiltrout et al.
patent: 5281620 (1994-01-01), Denny et al.
patent: 5464826 (1995-11-01), Grindey et al.
patent: 5620875 (1997-04-01), Hoffman et al.
patent: 5817684 (1998-10-01), Fleisch et al.
patent: 5863904 (1999-01-01), Nabel et al.
patent: 5910505 (1999-06-01), Fleisch et al.
patent: 6174873 (2001-01-01), Wrenn
patent: 6194454 (2001-02-01), Dow
patent: 6667337 (2003-12-01), Wilson
patent: 6806257 (2004-10-01), Lee et al.
patent: 2001/0041713 (2001-11-01), Waldstreicher et al.
patent: 2003/0003092 (2003-01-01), Krissansen et al.
patent: 2004/0087611 (2004-05-01), Baguley et al.
patent: 2004/0204480 (2004-10-01), Wilson et al.
patent: 2005/0131059 (2005-06-01), Wang et al.
patent: 2006/0009505 (2006-01-01), Baguley et al.
patent: 2007/0060637 (2007-03-01), Wilson et al.
patent: 2007/0082937 (2007-04-01), Baguley et al.
patent: 2008/0070848 (2008-03-01), Wilson et al.
patent: 2008/0070849 (2008-03-01), Wilson et al.
patent: 2008/0070886 (2008-03-01), Wilson et al.
patent: 2015265 (1970-10-01), None
patent: 19721211 (1998-11-01), None
patent: 0278176 (1988-08-01), None
patent: 0326149 (1989-08-01), None
patent: 0385467 (1990-09-01), None
patent: 0488718 (1992-06-01), None
patent: 0551200 (1993-07-01), None
patent: 0743064 (1996-11-01), None
patent: 0584001 (1997-05-01), None
patent: 0121285.1 (2001-09-01), None
patent: 0206839.3 (2002-05-01), None
patent: 0225508.1 (2002-11-01), None
patent: 0604114.9 (2006-03-01), None
patent: 0157387.7 (2006-08-01), None
patent: 0517386.9 (2006-08-01), None
patent: 09040690 (1997-02-01), None
patent: 2001247459 (2001-09-01), None
patent: 336259 (1999-06-01), None
patent: 506060 (2000-07-01), None
patent: 99121332 (2001-07-01), None
patent: 2195946 (2003-01-01), None
patent: WO 91/04014 (1991-04-01), None
patent: WO 94/23753 (1994-10-01), None
patent: WO 95/09621 (1995-04-01), None
patent: WO 96/32418 (1996-10-01), None
patent: WO 96/36347 (1996-11-01), None
patent: WO 97/04761 (1997-02-01), None
patent: WO 97/34482 (1997-09-01), None
patent: WO 98/25600 (1998-06-01), None
patent: WO 98/25615 (1998-06-01), None
patent: WO 98/25616 (1998-06-01), None
patent: WO 98/42332 (1998-10-01), None
patent: WO 98/42334 (1998-10-01), None
patent: WO 98/42335 (1998-10-01), None
patent: WO 98/42336 (1998-10-01), None
patent: WO 98/42337 (1998-10-01), None
patent: WO 98/42345 (1998-10-01), None
patent: WO 98/42346 (1998-10-01), None
patent: WO 98/42650 (1998-10-01), None
patent: WO 00/10600 (2000-03-01), None
patent: WO 00/15176 (2000-03-01), None
patent: WO 00/16798 (2000-03-01), None
patent: WO 00/48591 (2000-08-01), None
patent: WO 00/76497AI (2000-12-01), None
patent: WO 01/34135 (2001-05-01), None
patent: WO 01/34137 (2001-05-01), None
patent: WO 01/34197 (2001-05-01), None
patent: WO 01/34198 (2001-05-01), None
patent: WO 02/09700 (2002-02-01), None
patent: WO 03/020259 (2003-03-01), None
patent: WO 03/080044 (2003-10-01), None
patent: WO 2004/039363 (2004-05-01), None
patent: WO 2005/027974 (2005-03-01), None
patent: WO 2007/023302 (2007-03-01), None
patent: WO 2007/023307 (2007-03-01), None
patent: WO 2009/053681 (2009-04-01), None
Calabresi et al, Goodman and Gilman's , The pharmacological basis of therapeutics, 9thedition, 1995.
Calabresi et al, Antineoplastic agents, Chapter 52, in Goodman and Gilman's, The pharmacological basis of therapeutics, 1990 edition, pp. 1236-1238.
Siemann et al., abstract only, Proceedings of the American Association for Cancer Research, 2000, vol. 41, p. 525.
U.S. Appl. No. 12/064,632, filed Aug. 28, 2006, Green, et al.
U.S. Appl. No. 12/064,633, filed Aug. 25, 2006, Green, et al.
Aitken, et al.; “Synthesis and Antitumour Activity of New Derivatives of Flavone-8-acetic Acid (FAA), Part 4: Variation of the Basic Structure”; Arch. Pharm. Pharm. Med. Chem. (2000), 333(6):181-188.
Arbuck, et al.; “An Overview of Topoisomerase I—Targeting Agents”; Semin. Hematol. 1998, 35(3 supp.4):3-12.
Atwell, et al.; “Potential Antitumor Agents. 60. Relationships between Structure and in Vivo Colon 38 Activity for 5-Substituted 9-Oxoxanthene-4-acetic Acids”; J. Med. Chem. (1990), 33:1375-1379.
Atwell, et al.; “Synthesis and anti-tumor activity of topologically-related analogues of flavoneacetic acid”; Anti-Cancer Drug Design (1989), 4(2):161-169.
Avastin. Http://www.centerwatch.com/patient/drugs/dru851.html, Jun. 29, 2004.
Baguley, et al.; “Immunomodulatory Actions of Xanthenone Anticancer Agents”; BioDrugs; (1997), 8(2):119-127.
Baguley, et al.; “Mechanisms of Tumor Blood Flow Inhibition by The Antitumour Drug DMXAA (5,6-dimethylxanthenone-4-acetic acid”; Proceedings of the 11th NCI EORTC AACR Symposium; Copyright @ 2000 Stichting NCI-EORTC Symposium on new drugs in cancer therapy; publ. By the AACR; Published as a Supplement to Clinical Cancer Research, vol. 6, Nov. 2000.
Baguley, et al.; Poster Abstract 138, of abstracts book for the 16th EORTC-NCI-AACR 2004 meeting on “Molecular Targets and Cancer Therapeutics”; Geneva, Switzerland (Sep. 28 to Oct. 1, 2004).
Baguley, et al.; “Potential of DMXAA combination therapy for solid tumors”; Expert Rev. Anticancer Ther. (2002), 2(5):593-603.
Baguley, et al.; “Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5, 6-dimethylxanthenone-4-acetic acid”; Cancer Chemother. Pharmacol (1993), 33(1):77-81.
Baguley, et al.; “Evidence that the 5-hydroxytryptamine antagonist, cyproheptadine, modulates nitric oxide production in mice in response to flavone acetic acid, vinblastine and other agents”; Biol. Nitric Oxide, Proc. Int. Meet.; Meeting Date 1991, vol. 2, (1992); 222-224.
Baguley, et al.; “Increased Plasma Serotonin Following Treatment With Flavone-8-Acetic Acid, 5,6-Dimethylxanthenone-4-Acetic Acid, Vinblastine, and Colchicine: Relation to Vascular Effects”; Oncology Research; (1997) 9(2), 55-60.
Barefoot, R.; “Speciation of platinum compounds: a review of recent applications in studies of platinum anticancer drugs”; Journal of Chromatography B (2001), 751:205-211.
Begley, et al.; “The Blood-Brain-Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System”; J. Pharm. Pharmacol. (1996), 48:136-146.
Bibby, et al.; “Flavone acetic acid—from laboratory to clinic and back”; Anti-Cancer Drugs (1993), 4:3-17.
Bibby, et al.; “Reduction of Tumor Blood Flow by Flavone Acetic Acid: A Possible Component of Therapy”; J. Natl. Cancer Inst. (1989), 81:216-220.
Brem, et al.; “Interstitial chemotherapy with drug polymer implants for the treatment of recurring gliomas”; J. Neurosurg. (1991), 74:441-446.
Browne, et al.; “Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5, 6-dimethylxanthenone-4-acetic acid”; Anticancer Res. (1998), 18(6A):4409-4414.
Calabresi, et al.; “The Pharmacological Basis of Therapeutics, Ninth Edition,” (1996), Goodman & Gilman's The Pharmacological Basis of Therapeutics. Section X, Chemotherapy of Neoplastic Diseases, pp. 1225-1229.
Cao, et al.; “Interferon-inducible Protein 10 Induction and Inhibition of Angiogenesis
Siim Bronwyn G.
Wilson William R.
Cancer Research Technology Limited
Marschel Ardin
Nelson Mullins Riley & Scarborough LLP
Rao Savitha
Trinque Brian C.
LandOfFree
Anti-cancer combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-cancer combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer combinations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678670